Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections and rare diseases.
Spero’s lead product candidate, SPR994, is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections.
Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of rare, orphan disease caused by pulmonary non-tuberculous mycobacterial (NTM) infections.
Spero also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Spero’s lead product candidates generated from its Potentiator Platform are two IV-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting.
Copyright West LLC. Minimum 15 minutes delayed.
- April 08, 2019 Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases
- March 29, 2019 Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis
- March 19, 2019 Spero Announces Appointment of Cynthia Smith to its Board of Directors